Home›Trial›NCT05777993
NCT05777993Phase 4ENROLLING BY INVITATION

A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study

Study Summary

The purpose of this study is to provide continued access to mitapivat for participants who completed an Agios-sponsored mitapivat study (antecedent) and do not have commercial access to mitapivat.

Conditions
Pyruvate Kinase DeficiencyAnemia, Hemolytic
Interventions / Drugs
Mitapivat
View on ClinicalTrials.gov ↗
Sponsor
AGIO
Agios Pharmaceuticals
Rare Disease
A88/100
Study Details
Enrollment6 participants
Primary Completion—
Lead SponsorAgios Pharmaceuticals, Inc.
Data Retrieved2026-04-11 02:52:46.814934+00:00
What This Trial Means for Biotech Investors
Trial Phase Context

This trial phase represents an early or specialized stage of clinical development.

Status & Expected Data

Current status: ENROLLING BY INVITATION.

Enrolled: 6 participants
Sponsor Catalyst Profile

Agios Pharmaceuticals (AGIO) is the sponsoring company for this trial. BiotechSign currently grades this company A (88/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

AGIO Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.